Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants (Q44475690)

3 December 2017

Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants (English)

1 reference

3 December 2017

0 references

human papillomavirus 16

1 reference

7

Yu-Kyoung Oh

1 reference

3 December 2017

5

Young Bong Kim

1 reference

3 December 2017

4

Jung Mogg Kim

1 reference

3 December 2017

Hee-Jeong Cho

1

1 reference

3 December 2017

Ji-Yeon Kim

series ordinal

2

1 reference

3 December 2017

Young Lee

series ordinal

3

1 reference

3 December 2017

Taehoon Chun

series ordinal

6

1 reference

3 December 2017

language of work or name

English

0 references

publication date

28 January 2010

1 reference

3 December 2017

1 reference

3 December 2017

28

1 reference

3 December 2017

14

1 reference

3 December 2017

2598-2606

1 reference

Mucosal delivery of vaccine antigens and its advantages in pediatrics

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Universal influenza vaccination and live attenuated influenza vaccination of children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Sublingual vaccination with influenza virus protects mice against lethal viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Prospects for cervical cancer prevention by human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Expression, purification, and antibody binding activity of human papillomavirus 16 L1 protein fused to maltose binding protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Thermosensitive and mucoadhesive delivery systems of mucosal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Targeting the innate immune response with improved vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Intracellular NOD-like receptors in host defense and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.013

10.1016/J.VACCINE.2010.01.013

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference